These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 21537162

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2.
    Lambropoulos AF, Foka Z, Makris M, Daly M, Kotsis A, Makris PE.
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):485-9. PubMed ID: 9491265
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
    Svensson PJ, Zöller B, Dahlbäck B.
    Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
    [Abstract] [Full Text] [Related]

  • 28. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A.
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [Abstract] [Full Text] [Related]

  • 29. Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
    Herskovits AZ, Lemire SJ, Longtine J, Dorfman DM.
    Am J Clin Pathol; 2008 Nov; 130(5):796-804. PubMed ID: 18854273
    [Abstract] [Full Text] [Related]

  • 30. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Scudla V, Budíková M, Petrová P, Minarík J, Pika T, Bacovský J, Adamová D, Langová K, Ceská myelomová skupina.
    Klin Onkol; 2010 Nov; 23(3):171-81. PubMed ID: 20608327
    [Abstract] [Full Text] [Related]

  • 31. Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C.
    Ghansah H, Debreceni IB, Váróczy L, Rejtő L, Lóczi L, Bagoly Z, Kappelmayer J.
    Thromb Res; 2023 Mar; 223():44-52. PubMed ID: 36708689
    [Abstract] [Full Text] [Related]

  • 32. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.
    Halapi E, Werner A, Wahlström J, Osterborg A, Jeddi-Tehrani M, Yi Q, Janson CH, Wigzell H, Grunewald J, Mellstedt H.
    Eur J Immunol; 1997 Sep; 27(9):2245-52. PubMed ID: 9341766
    [Abstract] [Full Text] [Related]

  • 33. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N, Voorhees PM, Mackman N, Key NS.
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [Abstract] [Full Text] [Related]

  • 34. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
    Rolla R, Vidali M, Meola S, Pollarolo P, Pergolini P, Bellomo G.
    Clin Lab; 2011 Jul; 57(9-10):711-7. PubMed ID: 22029186
    [Abstract] [Full Text] [Related]

  • 35. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V, Ordeltova M, Bacovsky J, Vytrasova M, Sumna E, Martinek A, Horak P.
    Neoplasma; 2003 Jul; 50(5):363-71. PubMed ID: 14628090
    [Abstract] [Full Text] [Related]

  • 36. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.
    Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M.
    Haematologica; 2001 Apr; 86(4):394-8. PubMed ID: 11325645
    [Abstract] [Full Text] [Related]

  • 37. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.
    Torres JD, Cardona H, Alvarez L, Cardona-Maya W, Castañeda SA, Quintero-Rivera F, Cadavid A, Bedoya G, Tobón L.
    Am J Hematol; 2006 Dec; 81(12):933-7. PubMed ID: 16917913
    [Abstract] [Full Text] [Related]

  • 38. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance.
    Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):827-32. PubMed ID: 20332755
    [Abstract] [Full Text] [Related]

  • 39. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M, Stocker C, Bühler B, Conell B, Calatzis A.
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [Abstract] [Full Text] [Related]

  • 40. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL.
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.